Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 3/20 | 0.58 |
| ▸ | ECE1 | P42892 | 6/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24301726 | 0.91 | ACE (0.52) | ALOX15ACEECE1TACR1 | |
| SCHEMBL24301727 | 0.91 | ECE1 (0.55) | ALOX15ACEECE1TACR1 | |
| SCHEMBL24301768 | 0.91 | ALOX15 (0.53) | ALOX15ACEECE1ERAP2 | |
| SCHEMBL24302063 | 0.91 | SMN1; SMN2 (0.56) | ALOX15ACETACR1 | |
| SCHEMBL24301730 | 0.91 | SMN1; SMN2 (0.56) | ALOX15ACETACR1 | |
| SCHEMBL24301938 | 0.90 | ACE (0.55) | ALOX15ACEECE1ERAP2 | |
| SCHEMBL24302207 | 0.90 | MMP9 (0.62) | ALOX15ACEECE1TACR1 | |
| SCHEMBL24301723 | 0.90 | MAPT (0.57) | TACR1 | |
| SCHEMBL24301536 | 0.90 | BCL2A1 (0.51) | ALOX15ACETACR1 | |
| SCHEMBL24301722 | 0.90 | BCL2A1 (0.51) | ALOX15ACETACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261117-A1 | COMBINATION THERAPY WITH A DON PRODRUG AND A TIGIT INHIBITOR | DRACEN PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220117938-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | DRACEN PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2022078462-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2020150639-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | DRACEN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117938-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | PDCD1, CD274, BID | ALOX15 1797/4885ACE 751/4885ECE1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.